KIT is highly expressed in the majority of leukemic blasts [54, 55], and KIT mutations, most commonly affecting exons 8 and 17 (especially D816 mutations), are identified in approximately 25% of AML with core binding factor (CBF) rearrangements [56–59], but infrequently found in other AML types [20]. Here, CEBPZ is linked to acute myeloid leukemia.